James W. Tetrud

9.9k total citations · 4 hit papers
34 papers, 7.0k citations indexed

About

James W. Tetrud is a scholar working on Neurology, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, James W. Tetrud has authored 34 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Neurology, 10 papers in Cellular and Molecular Neuroscience and 6 papers in Neurology. Recurrent topics in James W. Tetrud's work include Parkinson's Disease Mechanisms and Treatments (28 papers), Neurological disorders and treatments (17 papers) and Neurological diseases and metabolism (5 papers). James W. Tetrud is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (28 papers), Neurological disorders and treatments (17 papers) and Neurological diseases and metabolism (5 papers). James W. Tetrud collaborates with scholars based in United States, Canada and Sweden. James W. Tetrud's co-authors include J. William Langston, Ian Irwin, Philip L. Ballard, J. William Langston, P. Ballard, Lysia S. Forno, Alexander G. Reeves, Jordan Kaplan, Barry Snow and Håkan Widner and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

James W. Tetrud

34 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis

1983 3.6k citations J. William Langston, Philip L. Ballard et al. Science profile →
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

1999 743 citations J. William Langston, Lysia S. Forno et al. Annals of Neurology profile →
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease

1989 503 citations James W. Tetrud, J. William Langston Science profile →
Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

1985 449 citations P. Ballard, James W. Tetrud et al. Neurology profile →

Peers

James W. Tetrud

NEURO

CMN

NEURO

PHYSI

J. William Langston United States

Baptiste Faucheux France

Ian Irwin United States

Fabio Blandini Italy

Paul M. Carvey United States

Patricia K. Sonsalla United States

Ranjita Betarbet United States

Teresa G. Hastings United States

Ali H. Rajput Canada

Susan E. Daniel United Kingdom

J. William Langston United States

James W. Tetrud

4.1k ×0.9

NEURO

3.1k ×0.9

CMN

1.2k ×0.7

823 ×0.8

NEURO

617 ×0.8

PHYSI

Citations per year, relative to James W. Tetrud James W. Tetrud (= 1×) peers J. William Langston

Countries citing papers authored by James W. Tetrud

Since Specialization

Citations

This map shows the geographic impact of James W. Tetrud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Tetrud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Tetrud more than expected).

Fields of papers citing papers by James W. Tetrud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James W. Tetrud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Tetrud. The network helps show where James W. Tetrud may publish in the future.

Co-authorship network of co-authors of James W. Tetrud

This figure shows the co-authorship network connecting the top 25 collaborators of James W. Tetrud. A scholar is included among the top collaborators of James W. Tetrud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. Tetrud. James W. Tetrud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Seongseop, Krisztina K. Johansen, Anne Lynn S. Chang, et al.. (2018). Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson’s disease. npj Parkinson s Disease. 4(1). 18–18. 24 indexed citations

Tetrud, James W., Paul A. Nausieda, Grace Liang, et al.. (2016). Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Journal of the Neurological Sciences. 373. 116–123. 4 indexed citations

Goldman, Samuel M., Grace S. Bhudhikanok, Monica Korell, et al.. (2014). Heart Rate Variability in LRRK2 Parkinson’s Disease (S37.004). Neurology. 82(10_supplement). 1 indexed citations

Mak, Sally K., et al.. (2011). Mitochondrial Dysfunction in Skin Fibroblasts from a Parkinson's Disease Patient with an alpha-Synuclein Triplication. Journal of Parkinson s Disease. 1(2). 175–183. 25 indexed citations

Lyons, Kelly E., Joseph H. Friedman, Neal Hermanowicz, et al.. (2010). Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects. Clinical Neuropharmacology. 33(1). 5–10. 31 indexed citations

Addy, Carol, C. Assaid, David Hreniuk, et al.. (2009). Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease. The Journal of Clinical Pharmacology. 49(7). 856–864. 51 indexed citations

LeWitt, Peter A., Mark Guttman, James W. Tetrud, et al.. (2008). Adenosine A _2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005). Annals of Neurology. 63(3). 295–302. 281 indexed citations

Tetrud, James W.. (2007). Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease. CNS Spectrums. 12(4). 275–286. 4 indexed citations

Tetrud, James W., et al.. (2006). Novel features in a patient homozygous for the L347P mutation in the PINK1 gene. Parkinsonism & Related Disorders. 13(6). 359–361. 11 indexed citations

10.

Murphy, Marjorie A, Joseph H. Friedman, James W. Tetrud, & Stewart A. Factor. (2005). Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases. Journal of Clinical Neuroscience. 12(8). 941–945. 5 indexed citations

11.

Burkhard, Pierre R., J. William Langston, & James W. Tetrud. (2002). Voluntarily simulated tremor in normal subjects. Neurophysiologie Clinique. 32(2). 119–126. 38 indexed citations

12.

Weiner, William J., Stewart A. Factor, Joseph Jankovic, et al.. (2001). The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism & Related Disorders. 7(2). 115–120. 29 indexed citations

13.

Langston, J. William, et al.. (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology. 46(4). 598–605. 743 indexed citations breakdown →

14.

Burkhard, Pierre R., Heidi Shale, J. William Langston, & James W. Tetrud. (1999). Quantification of dyskinesia in Parkinson's disease: Validation of a novel instrumental method. Movement Disorders. 14(5). 754–763. 38 indexed citations

15.

Tetrud, James W., Lawrence I. Golbe, Lysia S. Forno, & Peter Farmer. (1996). Autopsy-proven progressive supranuclear palsy in two siblings. Neurology. 46(4). 931–934. 36 indexed citations

16.

Vingerhoets, François, B. J. Snow, James W. Tetrud, et al.. (1994). Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions. Annals of Neurology. 36(5). 765–770. 109 indexed citations

17.

Doty, Richard L., et al.. (1992). Lack of major olfactory dysfunction in MPTP‐induced parkinsonism. Annals of Neurology. 32(1). 97–100. 77 indexed citations

18.

Widner, Håkan, James W. Tetrud, Stig Rehncrona, et al.. (1992). Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by 1-Methyl-4-Phenyl-L,2,3,6-Tetrahydropyridine (MPTP). New England Journal of Medicine. 327(22). 1556–1563. 369 indexed citations

19.

Ballard, P., James W. Tetrud, & J. William Langston. (1985). Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Neurology. 35(7). 949–949. 449 indexed citations breakdown →

20.

Langston, J. William, Philip L. Ballard, James W. Tetrud, & Ian Irwin. (1983). Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis. Science. 219(4587). 979–980. 3646 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact